Lysine-specific demethylase 1 (LSD1), which demethylates mono-and dimethylated histone H3-Lys4 as part of a complex including CoREST and histone deacetylases (HDACs), is essential for embryonic development in the mouse beyond embryonic day 6.5 (e6.5). To determine the role of LSD1 during this early period of embryogenesis, we have generated loss-of-function gene trap mice and conditional knockout embryonic stem ( The methylation of lysine residues within histones H3 and H4 helps to regulate the higher-order structure of chromatin in eukaryotic genomes. The consequences of lysine methylation on gene expression (unlike acetylation) can be either positive or negative, depending on the context of a particular lysine residue and the number of methyl moieties added (24, 27). Trimethylation of K9 on histone H3 (H3K9me3), for example, is generally associated with silenced genes and constitutive heterochromatin. In contrast, trimethylation of K4 on the same histone, H3 (H3K4me3), is associated with transcriptionally active regions. These methylated lysine residues provide the docking sites for the subsequent binding of chromatin-associated proteins with a cognate chromodomain, plant homeo domain (PHD) finger, or Tudor domain (42). Thus, the four methylated states of each specific lysine (unmodified or mono-, di-, or trimethylated) are interpreted by the association of other factors, such as the binding of HP1␣ to trimethyl H3 Lys9 (3, 29), which modify chromatin directly or indirectly. Lysine methylation in vivo is controlled by the opposing activities of lysine methyltransferases (KMTs) and lysine demethylases (KDMs). KDMs appear in two varieties: the amine oxidases, of which there are two (lysine-specific demethylase 1

Cellular senescence is a terminal differentiation state that has been proposed to have a role in both tumour suppression and ageing. This view is supported by the fact that accumulation of senescent cells can be observed in response to oncogenic stress as well as a result of normal organismal ageing. Thus, identifying senescent cells in in vivo and in vitro has an important diagnostic and therapeutic potential. The molecular pathways involved in triggering and/or maintaining the senescent phenotype are not fully understood. As a consequence, the markers currently utilized to detect senescent cells are limited and lack specificity. In order to address this issue, we screened for plasma membrane-associated proteins that are preferentially expressed in senescent cells. We identified 107 proteins that could be potential markers of senescence and validated 10 of them (DEP1, NTAL, EBP50, STX4, VAMP3, ARMX3, B2MG, LANCL1, VPS26A and PLD3). We demonstrated that a combination of these proteins can be used to specifically recognize senescent cells in culture and in tissue samples and we developed a straightforward fluorescence-activated cell sorting-based detection approach using two of them (DEP1 and B2MG). Of note, we found that expression of several of these markers correlated with increased survival in different tumours, especially in breast cancer. Thus, our results could facilitate the study of senescence, define potential new effectors and modulators of this cellular mechanism and provide potential diagnostic and prognostic tools to be used clinically.

Epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, is over-expressed in many tumors, including almost half of triple-negative breast cancers. The latter belong to a very-aggressive and drug-resistant form of malignancy. Although humanized anti-EGFR antibodies can work efficiently against these cancers both as monotherapy and in combination with genotoxic drugs, instability and high production costs are some of their known drawbacks in clinical use. In addition, the development of antibodies to target membrane proteins is a very challenging task. Accordingly, the main focus of the present work is the design of supramolecular agents for the targeting of membrane proteins in cancer cells and, hence, more-specific drug delivery. These were produced using a novel double-imprinting approach based on the solid-phase method for preparation of molecularly imprinted polymer nanoparticles (nanoMIPs), which were loaded with doxorubicin and targeted toward a linear epitope of EGFR. Additionally, upon binding, doxorubicin-loaded anti-EGFR nanoMIPs elicited cytotoxicity and apoptosis only in those cells that over-expressed EGFR. Thus, this approach can provide a plausible alternative to conventional antibodies and sets up a new paradigm for the therapeutic application of this class of materials against clinically relevant targets. Furthermore, nanoMIPs can promote the development of cell imaging tools against difficult targets such as membrane proteins.